> 资讯

资讯

2024-05-09 09:22:59Novotech 发布精准肿瘤学格局白皮书,指出靶向治疗的当前趋势和机遇

波士顿, May 09, 2024 (GLOBE NEWSWIRE) -- Novotech 是一家提供全方位服务的全球性临床合同研究组织 (CRO),它与生物技术公司合作,加速各个阶段先进和新颖疗法的开发。其最近发布了一份颇具见地的白皮书,《精准...[详细]

2024-05-09 09:19:49Novotech 发布有关血脂异常和非小细胞肺癌全球临床试验概况的新报告

波士顿, May 09, 2024 (GLOBE NEWSWIRE) -- Novotech,一家以亚太地区为中心、具有全球执行能力的领先生物技术临床合同研究组织 (CRO) 于今日发布了关于血脂异常和非小细胞肺癌 (NSCLC) 的最新 2023 年全球临床试...[详细]

2024-05-09 09:06:28《都市晨报》聚焦:德必集团进驻徐州,打造中心商圈年轻力新标杆

今年以来,徐州中心商圈“彭城壹号”更名“德必·彭城壹号”,金龙湖高铁商务区“金龙湖新天地”更名“德必·金龙湖新天地”,据悉市政府原址“彭城大院”也即将更名“德必·彭城大院”。 以上种种变化,预示着徐州3座商...[详细]

2024-05-09 07:00:42Avance Clinical 在亚太地区进一步扩张,韩国新的临床运营

来源 Avance Clinical Avance Clinical 在亚太地区进一步扩张,韩国新的临床运营 在 2024 年韩国生物技术展览会上宣布设立首尔办事处 澳大利亚阿德莱德和美国北卡罗来纳州, 2024年5月9日 - (亚太商讯) - Avanc...[详细]

2024-05-09 03:00:58AB InBev Reports First Quarter 2024 Results

Consistent execution of our strategy delivered a 5.4% EBITDA increase with margin expansion, and 16% Underlying EPS growth Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): Regulate...[详细]

2024-05-09 02:59:25Galderma Receives Filing Acceptances for Nemolizumab in Prurigo Nodularis and Atopic Dermatitis in F

Galderma has received filing acceptances for nemolizumab for the treatment of patients with prurigo nodularis and for adolescents and adults with moderate-to-severe atopic dermatitis in Australia, Sin...[详细]

2024-05-09 02:57:55QVC Signs Multi-Year Contract Extensions with SES in Germany and the UK

Worldwide leader in video commerce extends long-standing partnership to continue broadcasting multiple HD and SD channels from SES’s prime 19.2 degrees East and 28.2/28.5 degrees East video neighbour...[详细]

2024-05-09 02:56:11INRED and SES to Provide High-Throughput Connectivity Across Colombia’s Amazonas

The Amazonas Digital initiative will see INRED leverage SES’s MEO satellites in Colombia to connect more than 500 homes, schools and government entities across the city of Leticia and other rural are...[详细]

2024-05-09 02:54:32SES to acquire Intelsat: Investor Relations Frequently Asked Questions

LUXEMBOURG--(BUSINESS WIRE)--SES S.A.: 1) What is the rationale of the transaction? What is the benefit for SES shareholders? This combination creates a stronger and more competitive multi-orbit op...[详细]

2024-05-09 02:49:24Visa宣布推出人工智能反欺诈解决方案以打击账户攻击

威胁方正在利用自动脚本和僵尸网络等尖端技术来扩大他们的银行卡测试攻击,从而以前所未有的规模和速度攻击漏洞。这些攻击被称为枚举攻击,每年造成运营支出和11亿美元的欺诈损失,1占全球欺诈的很大一部分。为了应对...[详细]

随机文章

热门文章